Effect of RGH-2716 on learning and memory deficits of young and aged rats in water-labyrinth.
RGH-2716 is a novel 1-oxa-3,8-diazaspiro[4.5] decan 2-one, which was published to have potent inhibitory effect on neuronal Na and Ca movement and stimulatory action on nerve growth factor (NGF)-production, as well as to show significant antiamnesic activity in experimental amnesia models. The aim of the present experiments was to study the effect of the compound on the learning process and on the different stages of memory using water-labyrinth in normal and memory impaired young animals, as well as to study cognitive effect of RGH-2716 on aged animals. At the doses of 0.5 mg/kg i.p. or 3 mg/kg p.o. given before daily swimming, this compound improved the learning process of young animals impaired by either diazepam (DIA) or scopolamine (SCOP). In retrograde amnesia model RGH-2716 (3 mg/kg p.o.) significantly ameliorated consolidation process and retrieval of information impaired by SCOP or DIA. Nimodipine and vinpocetine (10 mg/kg p.o.) showed moderate effect compared to RGH-2716. Aged rats pretreated with daily i.p. RGH-2716 performed the tasks with significantly fewer errors and shorter swimming time than untreated aged rats. When aged animals had to solve a new labyrinth problem, treated aged rats showed significantly better learning ability than aged controls. One month of oral treatment of aged rats with 3 mg/kg dose of RGH-2716 two times daily resulted in a "tendency-like" improvement in learning of aged Fischer 344 and spontaneously hypertensive (SH) rats. The present results make RGH-2716 an interesting compound for the treatment of cognitive disorders.
Paróczai
M
M
Pharmacological Research Centre, Gedeon Richter Ltd., Budapest, Hungary. m.paroczai@richter.hu
Kiss
B
B
Kárpáti
E
E
D000375:Aging / Q000523:psychology*; D000648:Amnesia, Retrograde / Q000517:prevention & control; D000818:Animals; D003975:Diazepam / Q000494:pharmacology; D007859:Learning Disabilities / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology*; D008568:Memory / Q000187:drug effects / Q000502:physiology*; D008569:Memory Disorders / Q000188:drug therapy / Q000503:physiopathology*; D018696:Neuroprotective Agents / Q000494:pharmacology; D009553:Nimodipine / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D012601:Scopolamine / Q000494:pharmacology; D013141:Spiro Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D013550:Swimming; D014748:Vinca Alkaloids / Q000494:pharmacology
C112326:1-oxa-3,8-diazaspiro(4.5)decan 2-one; D018696:Neuroprotective Agents; D013141:Spiro Compounds; D014748:Vinca Alkaloids; C013983:vinpocetine; D009553:Nimodipine; D012601:Scopolamine; D003975:Diazepam